Transurethral Ethanol Ablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: Long-Term Follow-Up

El‐Husseiny, Tamer; Buchholz, Noor

doi:10.1089/end.2010.0201

Cited by 33 publications

(14 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results were sustained to 1-year postprocedure 27 . A separate study with a 4-yr follow-up period suggested a sustained response in 73% of patients with the remaining 23% requiring retreatment 28 . There is a need for further evaluation with comparative data to further quantify the value of transurethral ethanol ablation of the prostate.…”

Section: Mechanicalmentioning

confidence: 93%

Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies

Christidis

McGrath

Perera

et al. 2017

Prostate International

View full text Add to dashboard Cite

The prevalence of benign prostatic hypertrophy (BPH) causing bothersome lower urinary tract symptoms increases with our ageing population. Treatment of BPH traditionally begins with medical therapy and surgical intervention is then considered for those whose symptoms progress despite treatment. Minimally invasive surgical therapies have been developed as an intermediary in the treatment of BPH with the aim of decreasing the invasiveness of interventions. These therapies also aim to reduce morbidity and dysfunction related to invasive surgical procedures.Multiple treatment options exist in this group including mechanical and thermo-ablative strategies. Emerging therapies utilizing differing technologies range from the established to the experimental. We review the current literature related to these minimally invasive therapies and the evidence of their effectiveness in treating BPH.The role of minimally invasive surgical therapies in the treatment of BPH is still yet to be strongly defined. Given the experimental nature of many of the modalities, further study is required prior to their recommendation as alternatives to invasive surgical therapy. More mature evidence is required for the analysis of durability of effect of these therapies to make robust conclusions of their effectiveness.

show abstract

Section: Mechanicalmentioning

confidence: 93%

Minimally invasive surgical therapies for benign prostatic hypertrophy: The rise in minimally invasive surgical therapies

Christidis

McGrath

Perera

et al. 2017

Prostate International

View full text Add to dashboard Cite

show abstract

“…Promising results have been reported, but also variability in clinical outcomes [17][18][19][20][21]. The majority of trials have demonstrated a significant reduction in symptoms and postvoid residual volume (PVR) as well as a significant improvement in maximal flow rate (Q max ) and quality of life (QoL); prostate volume also decreased significantly in the majority of studies [19][20][21][22][23].…”

Section: Ethanolmentioning

confidence: 99%

“…A few studies have reported positive long-term results [20,21]. For example, El-Husseiny and Buchholz [21] reported the results obtained 54 months after transurethral ethanol prostate ablation in 56 men with BPH/LUTS.…”

Section: Ethanolmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of lower urinary tract symptoms: Agents for intraprostatic injection

Andersson

2013

Scandinavian Journal of Urology

View full text Add to dashboard Cite

When the currently available pharmacotherapeutic principles used for treatment of male lower urinary tract symptoms (LUTS) fail, transurethral resection of the prostate still remains the widely applied gold-standard therapy, since the majority of minimally invasive therapies have not achieved the same efficacy and/or lack an evidence base to support their routine use. Intraprostatic injection therapy, which probably is the oldest minimally invasive surgical treatment, has not been widely used, but recent reports of successful treatments with several new agents have renewed interest in this approach. Anhydrous ethanol still seems to be one of the most extensively studied injectables to date, but intraprostatic injection of botulinum toxin has received much recent attention, with regard to both its mechanism of action and efficacy. In addition, other agents such as NX-1207 and PRX302 have been reported to have promising effects. Injection therapy, using the transperineal, transrectal and transurethral routes for delivery of the active compounds, seems to be an effective minimally invasive surgical therapy for LUTS associated with benign prostatic hyperplasia (BPH). However, further studies on mechanisms of action of the novel agents used, and controlled clinical trials documenting their efficacy and side-effects (which are largely lacking), are needed before their place in the treatment of BPH/LUTS can be properly assessed.

show abstract

“…Other minimally invasive treatments for BPH have been preformed successfully under local anesthesia with good results including transperineal microwave ablation of the prostate, radiofrequencyinduced thermotherapy of the prostate, transurethral ethanol ablation of the prostate, photoselective prostate vaporization and transurethral needle ablation of the prostate. [41][42][43][44][45] Furthermore, studies have shown that periprostatic nerve block can successfully be applied to procedures such as internal urethrotomy, transurethral incision of prostate and bladder biopsies or fulguration while providing excellent pain relief. Periprostatic nerve block has also been used effectively for other urologic procedures such as the placement of intraprostatic fiducial markers prior to external beam radiotherapy.…”

Section: Application Of Prostate Anesthesiamentioning

confidence: 99%